Literature DB >> 17192114

Rates and probabilities in economic modelling: transformation, translation and appropriate application.

Rachael L Fleurence1, Christopher S Hollenbeak.   

Abstract

Economic modelling is increasingly being used to evaluate the cost effectiveness of health technologies. One of the requirements for good practice in modelling is appropriate application of rates and probabilities. In spite of previous descriptions of appropriate use of rates and probabilities, confusions persist beyond a simple understanding of their definitions. The objective of this article is to provide a concise guide to understanding the issues surrounding the use of rates and probabilities reported in the literature in economic models, and an understanding of when and how to transform them appropriately. The article begins by defining rates and probabilities and shows the essential difference between the two measures. Appropriate conversions between rates and probabilities are discussed, and simple examples are provided to illustrate the techniques and pitfalls. How the transformed rates and probabilities may be used in economic models is then described and some recommendations are suggested.

Mesh:

Year:  2007        PMID: 17192114     DOI: 10.2165/00019053-200725010-00002

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  9 in total

Review 1.  Assessing quality in decision analytic cost-effectiveness models. A suggested framework and example of application.

Authors:  M Sculpher; E Fenwick; K Claxton
Journal:  Pharmacoeconomics       Date:  2000-05       Impact factor: 4.981

Review 2.  An introduction to Markov modelling for economic evaluation.

Authors:  A Briggs; M Sculpher
Journal:  Pharmacoeconomics       Date:  1998-04       Impact factor: 4.981

3.  Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies.

Authors:  Milton C Weinstein; Bernie O'Brien; John Hornberger; Joseph Jackson; Magnus Johannesson; Chris McCabe; Bryan R Luce
Journal:  Value Health       Date:  2003 Jan-Feb       Impact factor: 5.725

Review 4.  Review of guidelines for good practice in decision-analytic modelling in health technology assessment.

Authors:  Z Philips; L Ginnelly; M Sculpher; K Claxton; S Golder; R Riemsma; N Woolacoot; J Glanville
Journal:  Health Technol Assess       Date:  2004-09       Impact factor: 4.014

5.  Evidence-based and value-based formulary guidelines.

Authors:  Peter J Neumann
Journal:  Health Aff (Millwood)       Date:  2004 Jan-Feb       Impact factor: 6.301

6.  Modelling in economic evaluation: an unavoidable fact of life.

Authors:  M J Buxton; M F Drummond; B A Van Hout; R L Prince; T A Sheldon; T Szucs; M Vray
Journal:  Health Econ       Date:  1997 May-Jun       Impact factor: 3.046

7.  Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis.

Authors:  E R Myers; D C McCrory; K Nanda; L Bastian; D B Matchar
Journal:  Am J Epidemiol       Date:  2000-06-15       Impact factor: 4.897

8.  Determining transition probabilities: confusion and suggestions.

Authors:  D K Miller; S M Homan
Journal:  Med Decis Making       Date:  1994 Jan-Mar       Impact factor: 2.583

9.  Estimation of markov chain transition probabilities and rates from fully and partially observed data: uncertainty propagation, evidence synthesis, and model calibration.

Authors:  Nicky J Welton; A E Ades
Journal:  Med Decis Making       Date:  2005 Nov-Dec       Impact factor: 2.583

  9 in total
  54 in total

1.  Event and Cost Offsets of Switching 20% of the Type 1 Diabetes Population in Germany From Multiple Daily Injections to Continuous Subcutaneous Insulin Infusion: A 4-Year Simulation Model.

Authors:  York Francis Zöllner; Ralph Ziegler; Magnus Stüve; Julia Krumreich; Marion Schauf
Journal:  J Diabetes Sci Technol       Date:  2016-08-22

2.  Cost effectiveness of adjunctive quetiapine fumarate extended-release tablets with mood stabilizers in the maintenance treatment of bipolar I disorder.

Authors:  Tatia Chay Woodward; Eskinder Tafesse; Peter Quon; Arthur Lazarus
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

3.  Continuous time simulation and discretized models for cost-effectiveness analysis.

Authors:  Marta O Soares; Luísa Canto E Castro
Journal:  Pharmacoeconomics       Date:  2012-12-01       Impact factor: 4.981

4.  The cost-effectiveness of school-based eating disorder screening.

Authors:  Davene R Wright; S Bryn Austin; H LeAnn Noh; Yushan Jiang; Kendrin R Sonneville
Journal:  Am J Public Health       Date:  2014-07-17       Impact factor: 9.308

5.  Financial implications to Medicare from changing the dialysis modality mix under the bundled prospective payment system.

Authors:  Frank X Liu; Surrey M Walton; Robert Leipold; Deborah Isbell; Thomas A Golper
Journal:  Perit Dial Int       Date:  2014-10-07       Impact factor: 1.756

6.  Cost-effectiveness of additional catheter-directed thrombolysis for deep vein thrombosis.

Authors:  T Enden; S Resch; C White; H S Wik; N E Kløw; P M Sandset
Journal:  J Thromb Haemost       Date:  2013-06       Impact factor: 5.824

7.  Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT.

Authors:  Philip Hykin; A Toby Prevost; Sobha Sivaprasad; Joana C Vasconcelos; Caroline Murphy; Joanna Kelly; Jayashree Ramu; Abualbishr Alshreef; Laura Flight; Rebekah Pennington; Barry Hounsome; Ellen Lever; Andrew Metry; Edith Poku; Yit Yang; Simon P Harding; Andrew Lotery; Usha Chakravarthy; John Brazier
Journal:  Health Technol Assess       Date:  2021-06       Impact factor: 4.014

8.  Changing Cycle Lengths in State-Transition Models: Challenges and Solutions.

Authors:  Jagpreet Chhatwal; Suren Jayasuriya; Elamin H Elbasha
Journal:  Med Decis Making       Date:  2016-07-01       Impact factor: 2.583

9.  Cost-effectiveness of first-line treatments for patients with KRAS wild-type metastatic colorectal cancer.

Authors:  E M Ewara; G S Zaric; S Welch; S Sarma
Journal:  Curr Oncol       Date:  2014-08       Impact factor: 3.677

10.  Economic Evaluation of Stiripentol for Dravet Syndrome: A Cost-Utility Analysis.

Authors:  Jesse Elliott; Bláthnaid McCoy; Tammy Clifford; George A Wells; Doug Coyle
Journal:  Pharmacoeconomics       Date:  2018-10       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.